2024
Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma
Rahman S, Long J, Westvold S, Leapman M, Spees L, Hurwitz M, McManus H, Gross C, Wheeler S, Dinan M. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open 2024, 7: e248747. PMID: 38687479, PMCID: PMC11061765, DOI: 10.1001/jamanetworkopen.2024.8747.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaArea-level measuresRenal cell carcinomaPatient-level factorsSystemic therapyEthnic disparitiesRelative risk ratiosSocially vulnerable areasCell carcinomaMeasures of social vulnerabilityMedicare beneficiariesCohort studyFee-for-service Medicare Parts AOdds ratioReceipt of systemic therapyLogistic regressionArea-level characteristicsAssociated with lack of treatmentNon-Hispanic blacksRetrospective cohort studyIndividual-level demographicsNon-Hispanic whitesAssociated with disparitiesUS Medicare beneficiariesMeasures of disadvantage
2023
Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States.
Richman I, Long J, Soulos P, Wang S, Gross C. Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States. Annals Of Internal Medicine 2023, 176: 1172-1180. PMID: 37549389, PMCID: PMC10623662, DOI: 10.7326/m23-0133.Peer-Reviewed Original ResearchConceptsCumulative incidenceBreast cancerBreast cancer screeningUnscreened womenOlder womenCancer screeningBreast cancer-specific deathBreast cancer overdiagnosisService Medicare claimsRetrospective cohort studyCancer-specific deathBreast cancer deathsWomen 70 yearsHarms of overdiagnosisNational Cancer InstituteBreast cancer diagnosisCohort studyCancer overdiagnosisCancer deathSEER programMedicare claimsCancer InstituteOverdiagnosisGreater incidenceCancerDisparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Renal CellEthnicityFemaleHumansKidney NeoplasmsMaleMedicareUnited StatesWhiteConceptsOral anticancer agentsTherapy utilizationMedicare beneficiariesNon-Hispanic white raceMetastatic renal cell carcinomaNon-Hispanic black raceOlder US patientsUS Medicare beneficiariesRenal cell carcinomaLogistic regression modelsTherapy receiptMultivariable adjustmentSystemic therapyMale sexUS patientsCell carcinomaStudy criteriaBlack raceFemale sexPatient raceWhite raceImmunotherapyOutcomes persistSexPatientsUse of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation
Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerMixed-effects Poisson regressionPSA testingProstate biopsyProstate cancerEffects Poisson regressionMedicare beneficiariesPoisson regressionAdditional prostate biopsyRetrospective cohort studyProstate MRILocalized prostate cancerRepeat prostate biopsyRate of biopsyRace/ethnicityCensus tract povertyMedian followCohort studyMedian ageMonitoring testsProvider factorsPSA testClinical riskBiopsySociodemographic factors
2022
End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy
Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice 2022, 19: e213-e227. PMID: 36413741, PMCID: PMC9970274, DOI: 10.1200/op.22.00401.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaOral anticancer agentsDays of lifeRenal cell carcinomaEOL careSystemic therapySEER-MedicareHospital deathCell carcinomaLife careIntensive care unit admissionCancer informationAggressive EOL careHigh-quality EOLOral anticancer therapySystemic therapy useCare unit admissionMultivariable logistic regressionQuality of endUnit admissionED visitsOlder patientsYounger patientsHospital admissionTherapy use
2015
Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign
Makarov DV, Soulos PR, Gold HT, Yu JB, Sen S, Ross JS, Gross CP. Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign. JAMA Oncology 2015, 1: 185-194. PMID: 26181021, PMCID: PMC4707944, DOI: 10.1001/jamaoncol.2015.37.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBreast NeoplasmsCatchment Area, HealthChi-Square DistributionDiagnostic ImagingFemaleGuideline AdherenceHumansLogistic ModelsMaleMedicareMultivariate AnalysisPractice Guidelines as TopicPractice Patterns, Physicians'Predictive Value of TestsProstatic NeoplasmsResidence CharacteristicsRetrospective StudiesRisk FactorsSEER ProgramUnited StatesUnnecessary ProceduresConceptsLow-risk prostate cancerProstate cancerBreast cancerProstate cancer imagingFourth quartileLow-risk breast cancerBreast cancer imagingLow-risk prostateEnd Results-MedicareRetrospective cohort studyMultivariable logistic regressionChoosing Wisely campaignPatient-level analysisAppropriateness of careHospital referral regionsCancer imagingQuality of careInappropriate imagingCohort studyWisely campaignHealth care spendingLowest quartileOdds ratioPatient levelHRR level
2014
Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications
Killelea BK, Long JB, Chagpar AB, Ma X, Wang R, Ross JS, Gross CP. Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications. Journal Of The National Cancer Institute 2014, 106: dju159. PMID: 25031307, PMCID: PMC4155428, DOI: 10.1093/jnci/dju159.Peer-Reviewed Original ResearchConceptsEnd Results-MedicareBreast cancer stageCohort of womenEarly-stage tumorsBreast cancer screeningAdjunct imagingSignificant changesCancer screeningCancer stageIncidence rateBreast cancerAdjunct procedureOlder womenMedicare populationMedicare beneficiariesClinical practiceComputer-aided detectionPoisson regressionNational feeCohortBreast ultrasoundWomenEarlier cohortsLater cohortsMedicare spending
2013
The Cost of Breast Cancer Screening in the Medicare Population
Gross CP, Long JB, Ross JS, Abu-Khalaf MM, Wang R, Killelea BK, Gold HT, Chagpar AB, Ma X. The Cost of Breast Cancer Screening in the Medicare Population. JAMA Internal Medicine 2013, 173: 220-226. PMID: 23303200, PMCID: PMC3638736, DOI: 10.1001/jamainternmed.2013.1397.Peer-Reviewed Original ResearchConceptsBreast cancer screeningCancer screeningTreatment costsBetter breast cancer outcomesEnd Results-Medicare databaseService MedicareHigh screening costsWomen ages 66Breast cancer outcomesInitial cancer treatmentHospital referral region levelWomen 75 yearsInitial treatment costsEarly-stage cancerDigital screening mammographyCancer outcomesCancer incidenceCancer stageLowest quartileAge 66Breast cancerOlder womenMedicare populationComputer-aided detectionTreatment expendituresUse of Hospital-Based Acute Care Among Patients Recently Discharged From the Hospital
Vashi AA, Fox JP, Carr BG, D’Onofrio G, Pines JM, Ross JS, Gross CP. Use of Hospital-Based Acute Care Among Patients Recently Discharged From the Hospital. JAMA 2013, 309: 364-371. PMID: 23340638, PMCID: PMC3598620, DOI: 10.1001/jama.2012.216219.Peer-Reviewed Original ResearchConceptsAcute care hospitalsHospital-based acute careAcute care encountersED visitsHospital readmissionAcute careCare hospitalRelease visitsIndex hospitalizationReasons patientsCare encountersED treatUncomplicated benign prostatic hypertrophyUtilization Project State InpatientAcute care visitsDays of dischargeEmergency department visitsCommon reason patientsHospital readmission ratesAcute care servicesBenign prostatic hypertrophyUse of hospitalHealth care focusEffectiveness of transitionCare visits
2012
Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity
Yu JB, Soulos PR, Herrin J, Cramer LD, Potosky AL, Roberts KB, Gross CP. Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. Journal Of The National Cancer Institute 2012, 105: 25-32. PMID: 23243199, PMCID: PMC3536640, DOI: 10.1093/jnci/djs463.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiotherapyProstate cancerMedicare beneficiariesGenitourinary toxicityEarly toxicityProton radiotherapyMultivariable logistic regressionPatterns of careMain outcome measuresType of radiotherapyMedicare reimbursementClinical benefitRetrospective studyPRT patientsOutcome measuresComprehensive cohortPRT useIMRT patientsPatientsSociodemographic characteristicsRadiotherapyCancerLogistic regressionMonthsSignificant differencesAssessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population
Soulos PR, Yu JB, Roberts KB, Raldow AC, Herrin J, Long JB, Gross CP. Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population. Journal Of Clinical Oncology 2012, 30: 1601-1607. PMID: 22393088, PMCID: PMC3383112, DOI: 10.1200/jco.2011.39.4890.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleHumansLife ExpectancyMastectomy, SegmentalMedicareNeoplasm InvasivenessNeoplasm StagingPrognosisRadiotherapy, AdjuvantRisk AssessmentSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsUse of RTAdjuvant radiation therapyRadiation therapyOlder womenRT useLife expectancyBreast cancerMedicare populationEnd Results-Medicare dataStage I breast cancerStrata of ageCooperative group trialsI breast cancerBreast cancer careStrata of patientsHealth system characteristicsLog-binomial regressionShort life expectancySample of womenTreatment guidelinesCancer careInclusion criteriaGroup trialsMedicare beneficiariesClinical practice
2006
The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening.
Gross CP, McAvay GJ, Krumholz HM, Paltiel AD, Bhasin D, Tinetti ME. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Annals Of Internal Medicine 2006, 145: 646-53. PMID: 17088577, DOI: 10.7326/0003-4819-145-9-200611070-00006.Peer-Reviewed Original ResearchConceptsChronic illnessColorectal cancerChronic conditionsLife expectancyCancer stageEarly-stage colorectal cancerPopulation-based cancer registriesPatients 67 yearsRetrospective cohort studyStage I cancerAdministrative claims dataChronic condition groupsFinal study sampleYears of ageShort life expectancyCohort studyEffect of agePatient ageI cancerCancer RegistryCancer variesHealthy patientsIndividual patientsMedicare claimsAdministrative claims
1999
Management of Barrett's esophagus: a national study of practice patterns and their cost implications
Gross C, Canto M, Hixson J, Powe N. Management of Barrett's esophagus: a national study of practice patterns and their cost implications. The American Journal Of Gastroenterology 1999, 94: ajg1999806. PMID: 10606300, DOI: 10.1111/j.1572-0241.1999.01606.x.Peer-Reviewed Original ResearchConceptsHigh-grade dysplasiaDirect medical costsBarrett's esophagusEndoscopic surveillancePractice patternsMedical costsAge 45 yrNational cross-sectional surveyCurrent practice patternsLow-grade dysplasiaMajority of cliniciansFrequency of endoscopyDegree of dysplasiaPopulation-based estimatesCross-sectional surveySurveillance endoscopyNonclinical factorsBE patientsPhysician ageCost implicationsFrequent surveillanceDysplasiaGastroenterologistsClinical decisionOptimal management
1998
Will Commercial Managed Care Patients Accept Residents as Their Primary Care Providers?
Gross C, Callahan M, Mele J. Will Commercial Managed Care Patients Accept Residents as Their Primary Care Providers? Journal Of General Internal Medicine 1998, 13: 331-334. PMID: 9613890, PMCID: PMC1496953, DOI: 10.1046/j.1525-1497.1998.00100.x.Peer-Reviewed Original ResearchConceptsPrimary care providersCare patientsCare providersPatients' willingnessOutpatient careMedicare patientsHousestaff physiciansPrior careMedicare populationPatientsResident physiciansPayer classTelephone surveyCarePhysician's functionSignificant proportionMedical practicePhysiciansMedicaidProvidersResidents